ArticleClinical Medicine Insights. Oncology2026
Risk Factors for Febrile Neutropenia in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Undergoing Initial R-CHOP Treatment.
Article in Clinical Medicine Insights. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Febrile neutropenia in adults with diffuse large B-cell lymphoma receiving first-line R-CHOP-based therapy: a systematic review and meta-analysis of observational and trial evidence.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Febrile neutropenia (FN) frequently occurs as a complication among patients with diffuse large B-cell lymphoma (DLBCL) receiving their initial rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. This study aimed to identify the risk factors for FN and create a reliable predictive model for FN using machine learning methods. Methods: This retrospective study evaluated 238 patients newly diagnosed with DLBCL and treated with the R-CHOP regimen. Logistic regression was used to identify the risk factors for FN. In addition, a machine learning model was developed to predict the occurrence of FN. Results: The incidence rate of FN was 23.9%. Univariate analysis revealed significant associations between FN and bone marrow involvement (odds ratio [OR], 2.78; 95% confidence interval [CI], 1.36-5.66; Conclusions: Patients with DLBCL who develop FN after their first R-CHOP treatment have a significantly worse OS than those without FN. Tailored prophylaxis with granulocyte-colony stimulating factor and antibiotics may be essential in this population. Models with moderate to strong predictive power can be designed using various artificial intelligence techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.